Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

Todd Neale

December 26, 2025

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Daily News

Renal Denervation a Third Option for Hypertension, European Experts Say

Todd Neale

September 17, 2021

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

L.A. McKeown

August 10, 2021

News Daily News

Renal Denervation Lowers BP in Sham-Controlled Studies: Meta-Analysis

Michael O'Riordan

April 02, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Conference News EuroPCR 2018

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

Michael O'Riordan

May 23, 2018

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

New-Onset A-Fib, Chronic Kidney Disease Are Risk Factors For Stroke After TAVR, Meta-Analysis Shows

Yael L. Maxwell

August 10, 2016

News Daily News

Model Suggests Renal Denervation Cost-effective for Resistant Hypertension

September 13, 2012

Advertisement

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

August 2024 Dispatch for the CV Team

BP Reduction With Renal Denervation Still Evident a Decade On

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

December 2021 News Roundup

Renal Denervation a Third Option for Hypertension, European Experts Say

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

Renal Denervation Lowers BP in Sham-Controlled Studies: Meta-Analysis

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

New-Onset A-Fib, Chronic Kidney Disease Are Risk Factors For Stroke After TAVR, Meta-Analysis Shows

Model Suggests Renal Denervation Cost-effective for Resistant Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content